Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Adrenomed AG, corporate

Adrenomed AG,

30.08.2021 - 16:59:49

Adrenomed: Participation in Upcoming Scientific and Industry Events

Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.[2] For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter. ?

Contact Adrenomed AG Frauke Hein, Ph.D. (Chief Business Officer) phone: +49 (0)3302 2077814fhein@adrenomed.comMedia InquiriesMC Services AG Eva Bauer / Julia von Hummel phone: +49 (0)89 21022880adrenomed@mc-services.eu[1]Shock, 2018;50(6):648-654[2]https://www.nature.com/articles/d43747-021-00098-8

30.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1229804??30.08.2021?

@ dgap.de